Lonza Implements New One Lonza Operating Model

• Lonza has implemented a new streamlined operating model, effective today, as part of its One Lonza strategy.

• The restructuring includes three newly-formed CDMO business platforms and the planned separation of its Capsules & Health Ingredients (CHI) business.

Lonza has announced that its new simplified and streamlined operating model is now in effect. The restructuring follows the company’s One Lonza vision, first introduced in December 2024, and aims to enhance scalability, improve execution, and strengthen its multimodality offering.

The company’s operations are now structured into three newly-formed CDMO business platforms. Integrated Biologics, led by Gordon Bates, focuses on mammalian and drug product services. Advanced Synthesis, headed by Christian Seufert, combines hybrid chemistry and biology solutions, incorporating the former Small Molecules division and Bioconjugates. Specialized Modalities, under Daniel Palmacci, pioneers cell and gene technologies, mRNA, microbial, and bioscience.

The new structure removes the business unit layer, allowing each platform to directly manage multiple technology platforms. Meanwhile, the Capsules & Health Ingredients (CHI) business will continue to operate in its current form under the leadership of Jean-Christophe Hyvert. Lonza plans to divest CHI when the timing aligns with shareholder and stakeholder interests.

The restructuring is designed to improve customer experience and execution efficiency, including a unified go-to-market approach and enhanced asset management. The company will publish restated financials for 2024 in June, with its Half-Year 2025 results set for release on 23 July 2025.